FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330587564> ?p ?o ?g. }

• W2330587564 endingPage "826" @default.
• W2330587564 startingPage "816" @default.
• W2330587564 abstract "Objective: Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression. This study evaluated the efficacy of twice- and thrice-weekly intravenous administration of ketamine in sustaining initial antidepressant effects in patients with treatment-resistant depression. Method: In a multicenter, double-blind study, adults (ages 18–64 years) with treatment-resistant depression were randomized to receive either intravenous ketamine (0.5 mg/kg of body weight) or intravenous placebo, administered over 40 minutes, either two or three times weekly, for up to 4 weeks. Patients who discontinued double-blind treatment after at least 2 weeks for lack of efficacy could enter an optional 2-week open-label phase to receive ketamine with the same frequency as in the double-blind phase. The primary outcome measure was change from baseline to day 15 in total score on the Montgomery-Åsberg Depression Rating Scale (MADRS). Results: In total, 67 (45 women) of 68 randomized patients received treatment. In the twice-weekly dosing groups, the mean change in MADRS score at day 15 was −18.4 (SD=12.0) for ketamine and −5.7 (SD=10.2) for placebo; in the thrice-weekly groups, it was −17.7 (SD=7.3) for ketamine and −3.1 (SD=5.7) for placebo. Similar observations were noted for ketamine during the open-label phase (twice-weekly, −12.2 [SD=12.8] on day 4; thrice-weekly, −14.0 [SD=12.5] on day 5). Both regimens were generally well tolerated. Headache, anxiety, dissociation, nausea, and dizziness were the most common (≥20%) treatment-emergent adverse events. Dissociative symptoms occurred transiently and attenuated with repeated dosing. Conclusions: Twice-weekly and thrice-weekly administration of ketamine at 0.5 mg/kg similarly maintained antidepressant efficacy over 15 days." @default.
• W2330587564 created "2016-06-24" @default.
• W2330587564 creator A5001042943 @default.
• W2330587564 creator A5014334391 @default.
• W2330587564 creator A5015678331 @default.
• W2330587564 creator A5023527028 @default.
• W2330587564 creator A5029257842 @default.
• W2330587564 creator A5037185919 @default.
• W2330587564 creator A5047437809 @default.
• W2330587564 creator A5052697414 @default.
• W2330587564 creator A5067156584 @default.
• W2330587564 creator A5076010133 @default.
• W2330587564 creator A5084024326 @default.
• W2330587564 creator A5085501292 @default.
• W2330587564 creator A5087160785 @default.
• W2330587564 creator A5089284435 @default.
• W2330587564 creator A5091337532 @default.
• W2330587564 creator A5091766408 @default.
• W2330587564 date "2016-08-01" @default.
• W2330587564 modified "2023-10-14" @default.
• W2330587564 title "A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression" @default.
• W2330587564 cites W1742833546 @default.
• W2330587564 cites W1966424565 @default.
• W2330587564 cites W1969644317 @default.
• W2330587564 cites W1977471295 @default.
• W2330587564 cites W1993057480 @default.
• W2330587564 cites W2000031234 @default.
• W2330587564 cites W2000053835 @default.
• W2330587564 cites W2023081218 @default.
• W2330587564 cites W2054437388 @default.
• W2330587564 cites W2091363925 @default.
• W2330587564 cites W2097857685 @default.
• W2330587564 cites W2109334244 @default.
• W2330587564 cites W2111663098 @default.
• W2330587564 cites W2128918664 @default.
• W2330587564 cites W2131823335 @default.
• W2330587564 cites W2132324173 @default.
• W2330587564 cites W2142133137 @default.
• W2330587564 cites W2154962555 @default.
• W2330587564 cites W2468549818 @default.
• W2330587564 doi "https://doi.org/10.1176/appi.ajp.2016.16010037" @default.
• W2330587564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27056608" @default.
• W2330587564 hasPublicationYear "2016" @default.
• W2330587564 type Work @default.
• W2330587564 sameAs 2330587564 @default.
• W2330587564 citedByCount "349" @default.
• W2330587564 countsByYear W23305875642015 @default.
• W2330587564 countsByYear W23305875642016 @default.
• W2330587564 countsByYear W23305875642017 @default.
• W2330587564 countsByYear W23305875642018 @default.
• W2330587564 countsByYear W23305875642019 @default.
• W2330587564 countsByYear W23305875642020 @default.
• W2330587564 countsByYear W23305875642021 @default.
• W2330587564 countsByYear W23305875642022 @default.
• W2330587564 countsByYear W23305875642023 @default.
• W2330587564 crossrefType "journal-article" @default.
• W2330587564 hasAuthorship W2330587564A5001042943 @default.
• W2330587564 hasAuthorship W2330587564A5014334391 @default.
• W2330587564 hasAuthorship W2330587564A5015678331 @default.
• W2330587564 hasAuthorship W2330587564A5023527028 @default.
• W2330587564 hasAuthorship W2330587564A5029257842 @default.
• W2330587564 hasAuthorship W2330587564A5037185919 @default.
• W2330587564 hasAuthorship W2330587564A5047437809 @default.
• W2330587564 hasAuthorship W2330587564A5052697414 @default.
• W2330587564 hasAuthorship W2330587564A5067156584 @default.
• W2330587564 hasAuthorship W2330587564A5076010133 @default.
• W2330587564 hasAuthorship W2330587564A5084024326 @default.
• W2330587564 hasAuthorship W2330587564A5085501292 @default.
• W2330587564 hasAuthorship W2330587564A5087160785 @default.
• W2330587564 hasAuthorship W2330587564A5089284435 @default.
• W2330587564 hasAuthorship W2330587564A5091337532 @default.
• W2330587564 hasAuthorship W2330587564A5091766408 @default.
• W2330587564 hasBestOaLocation W23305875641 @default.
• W2330587564 hasConcept C126322002 @default.
• W2330587564 hasConcept C139719470 @default.
• W2330587564 hasConcept C142724271 @default.
• W2330587564 hasConcept C162324750 @default.
• W2330587564 hasConcept C168563851 @default.
• W2330587564 hasConcept C204787440 @default.
• W2330587564 hasConcept C27081682 @default.
• W2330587564 hasConcept C2776867660 @default.
• W2330587564 hasConcept C2777288759 @default.
• W2330587564 hasConcept C2777342061 @default.
• W2330587564 hasConcept C2779177272 @default.
• W2330587564 hasConcept C2780795376 @default.
• W2330587564 hasConcept C2781161787 @default.
• W2330587564 hasConcept C42219234 @default.
• W2330587564 hasConcept C71924100 @default.
• W2330587564 hasConceptScore W2330587564C126322002 @default.
• W2330587564 hasConceptScore W2330587564C139719470 @default.
• W2330587564 hasConceptScore W2330587564C142724271 @default.
• W2330587564 hasConceptScore W2330587564C162324750 @default.
• W2330587564 hasConceptScore W2330587564C168563851 @default.
• W2330587564 hasConceptScore W2330587564C204787440 @default.
• W2330587564 hasConceptScore W2330587564C27081682 @default.
• W2330587564 hasConceptScore W2330587564C2776867660 @default.
• W2330587564 hasConceptScore W2330587564C2777288759 @default.
• W2330587564 hasConceptScore W2330587564C2777342061 @default.

• next